Phase 2a trial in 103 participants with active RA despite advanced therapies: nipocalimab plus certolizumab vs certolizumab alone gave a similar DAS28-CRP change at week 12 (-1.92 vs -1.86; p=0.822). Serious adverse events 11.3% vs 2.4%.
RCTn = 103
Taylor et al. Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study